Alibaba Open-Sources RADAR, a Medical AI That Beat Most Radiologists on Abdominal CT Scans

Alibaba’s Damo Academy open-sourced Damo Radar on September 20, a vision-language model that analyzes contrast-enhanced abdominal CT scans and detects nearly 150 abdominal conditions including cancers, per South China Morning Post. The model was trained on over 420,000 contrast-enhanced abdominal CT examinations covering 18 abdominal organs with roughly 15 million anatomy-aware annotations, and achieved an average AUC of 0.913 across 146 clinical findings, tested on nearly 40,000 real-world examinations. In comparative testing, it outperformed 23 of 26 radiologists. The code and model are on GitHub, and the underlying research was published in Science.

Why the Training Scale Matters More Than the Benchmark

Medical AI models routinely post strong benchmarks on curated datasets and fail on real-world distributions. RADAR’s 420,000-examination training corpus with 15 million anatomy-aware annotations is notable because it was built from real clinical imaging across 18 organs, not a curated challenge set. The 40,000-examination test set is also drawn from real-world data rather than a held-out benchmark split, which means the 0.913 AUC reflects the distribution shift every deployed medical model faces. That distinction is the difference between a paper result and a deployable capability.

The Open-Source Decision Is the Strategic One

Alibaba open-sourcing RADAR follows its open-weight strategy for Qwen and positions DAMO Academy as the leading publisher of open medical AI models. The licensing terms matter enormously: open-source medical AI that hospitals can run on-premise serves a fundamentally different market than cloud-only models, and in markets where patient data cannot leave the hospital network (which is most of them), on-premise is the only deployment option. Alibaba also has COCA, its colorectal cancer detection model, in its medical AI portfolio, suggesting a deliberate strategy of open-sourcing horizontal medical AI capabilities.

What to Watch

Three things determine whether RADAR reaches patients. First, regulatory clearance: open-sourcing the weights is not FDA or NMPA approval, and medical imaging AI requires clinical validation per jurisdiction. Second, the radiologist community’s response: the model beat 23 of 26 radiologists on benchmarks, but real clinical adoption depends on integration into existing PACS workflows and radiologist trust. Third, whether other Chinese tech companies follow Alibaba’s open-source medical AI strategy, which would create a parallel ecosystem to the US cloud-dominated medical AI market. The medical AI adoption concerns the FT reported this week, citing limited clinical data beyond diagnostics, are the counterweight to the benchmark enthusiasm.